Avaliação das alterações genéticas em crianças e adolescentes com leucemia linfoblástica aguda, em um hospital universitário do Sul do Brasil, no período de 2000 a 2018.

• Autor(a) principal: Marcon, Mariana Nóbrega
• Data de Publicação: 2023
• Tipo de documento: Dissertação
• Idioma: por
• Título da fonte: Manancial - Repositório Digital da UFSM
• dARK ID: ark:/26339/00130000185s7
• Texto Completo: http://repositorio.ufsm.br/handle/1/29572
• topic: Genética; Pediatria; Recidiva; Sobrevida; Oncologia; Genetics; Oncology; Pediatrics; Recurrence; Survival; CNPQ::CIENCIAS DA SAUDE

Acute lymphoblastic leukemia (ALL) is diagnosed cytomorphologically by immunophenotyping, cytogenetics and molecular biology. The classifications, together with the clinical data, stratify the groups at risk of relapse, for a more or less invasive therapeutic decision. Carrying out genetic tests in the diagnosis is fundamental to outline a better prognosis and a more appropriate treatment in each case. This was a retrospective and cross-sectional study, which evaluated the profile of patients diagnosed with ALL in childhood and adolescence, their genetic alterations, prognosis, relapse/death outcome and survival, whose treatment was by the GBTLI ALL-1999 and GBTLI ALL- 2009, at the University Hospital of Santa Maria, from July 2000 to November 2018. There were 215 diagnoses of ALL, with a mean age of 7.45 years, 54.9% male. Stratified by relapse risk groups, 35.8% of patients were at High Risk, 41.9% at Low Risk, 15.3% with T Lineage ALL, 4.2% with Ph+ chromosome and 2.8% Infants. All patients had their cytogenetic and molecular biology tests analyzed and stratified by the main markers. When comparing the data from the GBTLI-LLA 1999 and GBTLI-LLA 2009 protocols, similarity was observed in relapse rates of 17.6% and 17.6% and in death rates of 22% and 21%, respectively. In the last three decades, with the treatment by clinical protocol, there has been an advance in the cure, and the survival rates reach 70 to 80%, which was evidenced in this study, with an overall survival of 87.9% in one year , 83.5% in two years and 79.8% in five years of patients treated by the GBTLI LLA-1999 protocol and 85.5% in one year, 83.95 in two years and 81.4% in five years of patients treated by GBTLI LLA-2009, showing similar survival rates.